Eversept Partners LP Purchases New Stake in Biohaven Ltd. $BHVN

Eversept Partners LP purchased a new stake in Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 145,431 shares of the company’s stock, valued at approximately $1,642,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. AQR Capital Management LLC lifted its stake in shares of Biohaven by 49.4% in the 1st quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock valued at $2,761,000 after purchasing an additional 37,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Biohaven by 32.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock valued at $1,747,000 after purchasing an additional 17,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Biohaven by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after purchasing an additional 41,040 shares during the period. Intech Investment Management LLC lifted its stake in shares of Biohaven by 80.3% in the 1st quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock valued at $1,481,000 after purchasing an additional 27,433 shares during the period. Finally, Quantbot Technologies LP boosted its holdings in Biohaven by 1,097.8% during the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after buying an additional 8,102 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Stock Up 13.2%

Shares of BHVN stock opened at $13.69 on Thursday. The firm has a fifty day moving average of $10.18 and a 200-day moving average of $10.57. The company has a quick ratio of 7.41, a current ratio of 7.41 and a debt-to-equity ratio of 1.87. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -2.41 and a beta of 1.35.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). As a group, equities research analysts predict that Biohaven Ltd. will post -3.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on BHVN. Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a report on Tuesday, June 2nd. HC Wainwright restated a “neutral” rating and set a $10.00 target price on shares of Biohaven in a report on Tuesday, May 26th. TD Cowen raised their target price on Biohaven from $15.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Citigroup raised their target price on Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Biohaven in a research note on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.27.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.